case_images: PMC6186340_01
case_images: Images taken 3 days after onset of symptoms. Fundus photo, yellowish white subretinal placoid lesions (a). FAF, placoid lesions with central hypoautofluorescence with hyperautofluorescent edges (b). OCT Fovea, top: OD and bottom: OS. RPE and ellipsoid zone attenuation of placoid lesions. Subretinal hyperreflective material (c). FA, left: early phase OS. Central and right: late phase OD and OS. Early blocking with late staining (d).
case_images: CRIOPM2018-1656131.001.jpg
case_images: PMC6186340_01_CRIOPM2018-1656131.001.jpg
case_images: fig1
case_images: There were, in the posterior pole of both eyes, multiple yellow-white chorioretinal placoid lesions more significant on the left eye (Figure 1(a)). Spectral domain optical coherence tomography showed the placoid lesions with disruption of the RPE, external limiting membrane, and ellipsoid zone as well as small focal points of hyperreflective material at the level of the ellipsoid zone (Figure 1(c)). Fundus autofluorescence (FAF) showed the placoid lesions to have hyperautofluorescence center with hypoautofluorescence edges (Figure 1(b)). Fluorescein angiogram showed the placoid lesions had the characteristic early blocking with late hyperfluorescent staining of edges (Figure 1(d)).
case_images: Images taken 3 months after onset of symptoms. Fundus photo, yellowish white subretinal placoid lesions smaller in size (a). FAF, placoid lesions with central hypoautofluorescence with hyperautofluorescent edges, smaller in size and boundaries less distinct (b). OCT Fovea, top: OD and bottom: OS. Much improved RPE and ellipsoid zone attenuation of placoid lesions and resolved subretinal hyperreflective material (c). FA, left: early phase OS. Central and right: late phase OD and OS. Early blocking with late staining less than before (d).
case_images: CRIOPM2018-1656131.002.jpg
case_images: PMC6186340_01_CRIOPM2018-1656131.002.jpg
case_images: fig2
case_images: OCT (Figures 2(b), 2(c), and 2(d)). On the 5-month follow-up, the BCVA was 20/20 OU.